Skip to content

Clinical trial of radionuclide myocardial perfusion combined with myocardial glucose metabolism imaging in accurate diagnosis and risk stratification of patients with suspected acute coronary syndrome

Clinical trial of radionuclide myocardial perfusion combined with myocardial glucose metabolism imaging in accurate diagnosis and risk stratification of patients with suspected acute coronary syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038033
Enrollment
Unknown
Registered
2020-09-08
Start date
2020-09-10
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected acute coronary syndrome

Interventions

Sponsors

The Third Affiliated Hospital of Soochow University/The First People's Hospital of Changzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with chest pain or chest tightness; 2. Patients with no significant increase of HS cTnI; 3. Patients with new or transient ST segment depression or T wave low, flat and inversion on ECG. According to the patient's history, symptoms and signs, combined with ECG and laboratory examination, the initial diagnosis of suspected ACS was made.

Exclusion criteria

Exclusion criteria: 1. Patients with unknown history and lack of important clinical data; 2. Patients with STEMI and NSTEMI diagnosed clinically; 3. Patients with cardiomyopathy, pulmonary heart disease, valvular heart disease and congenital heart disease; 4. Patients with severe liver and renal failure; 5. Patients with severe infection; 6. Patients with malignant tumor, radiotherapy and chemotherapy; 7. Patients with other serious metabolic diseases and other major diseases; 8. Patients who are expected to have poor compliance and cannot be visited regularly; 9. Pregnant women, lactating women or women of childbearing age who have fertility requirements; 10. There were other situations in which the researchers considered that it was not suitable to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Adverse cardiac events;SEN, SPE, ACC, AUC of ROC, PPV, NPV;

Countries

China

Contacts

Public ContactYuetao Wang

The Third Affiliated Hospital of Suzhou University / nuclear medicine discipline of Changzhou First People's Hospital

yuetao-w@163.com+86 13852040196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026